Point72 Asset Management’s Novavax NVAX Stock Holding History

Point72 Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$285K	Sell	35,000 -94,000	-73%	-$852K	﹤0.01%	3385
2025 Q4	$867K	Buy	129,000 +14,000	+12%	+$106K	﹤0.01%	2944
2025 Q3	$997K	Sell	115,000 -60,000	-34%	-$467K	﹤0.01%	1696
2025 Q2	$1.1M	Buy	175,000 +50,000	+40%	+$331K	﹤0.01%	1520
2025 Q1	$801K	Buy	+125,000	New	+$1.03M	﹤0.01%	1510
2024 Q4	–	Sell	-155,000	Closed	-$1.96M	–	2332
2024 Q3	$1.96M	Buy	155,000 +35,000	+29%	+$452K	0.01%	1201
2024 Q2	$1.52M	Buy	+120,000	New	+$1.21M	﹤0.01%	1169

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's NVAX Position: Q1 2026 in Review

Point72 Asset Management increased its Novavax (NVAX) stake by 9,138% in Q1 2026, buying an estimated $13.6M and bringing the position to 1,518,211 shares worth $12.4M. The position accounts for 0.02% of the portfolio, ranked #1097.

Point72 Asset Management first reported a position in NVAX in Q1 2015 and has held it in 10 quarters since. The position peaked at $64.7M in Q3 2020. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Point72 Asset Management held 1,518,211 shares of Novavax worth $12.4M as of Q1 2026.
Point72 Asset Management bought 1,501,776 Novavax shares in Q1 2026, an estimated $13.6M.
Novavax made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #1097 holding.
Point72 Asset Management first reported a position in Novavax in Q1 2015 and has held it in 10 quarters since.
Point72 Asset Management's Novavax position peaked at $64.7M in Q3 2020.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.